ResMed shares slumped and Eli Lilly shares gained after the FDA approved Eli Lilly's weight-loss treatment Zepbound for some patients with sleep apnea. Major U.S. indexes were mixed at midday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback